In last trading session, Janux Therapeutics Inc (NASDAQ:JANX) saw 0.67 million shares changing hands with its beta currently measuring 3.15. Company’s recent per share price level of $36.01 trading at -$1.16 or -3.12% at ring of the bell on the day assigns it a market valuation of $2.08B. That closing price of JANX’s stock is at a discount of -99.14% from its 52-week high price of $71.71 and is indicating a premium of 72.06% from its 52-week low price of $10.06.
For Janux Therapeutics Inc (JANX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.27. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Janux Therapeutics Inc (NASDAQ:JANX) trade information
Upright in the red during last session for losing -3.12%, in the last five days JANX remained trading in the red while hitting it’s week-highest on Friday, 02/21/25 when the stock touched $36.01 price level, adding 6.27% to its value on the day. Janux Therapeutics Inc’s shares saw a change of -32.74% in year-to-date performance and have moved -3.12% in past 5-day. Janux Therapeutics Inc (NASDAQ:JANX) showed a performance of -10.38% in past 30-days.
Wall Street analysts have assigned a consensus price target of 70 to the stock, which implies a rise of 48.56% to its current value. Analysts have been projecting 69 as a low price target for the stock while placing it at a high target of 100. It follows that stock’s current price would drop -91.61% in reaching the projected high whereas dropping to the targeted low would mean a loss of -91.61% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -92.62% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -11.44% while estimates for its earnings growth in next 5 years are of -24.84%.
Janux Therapeutics Inc (NASDAQ:JANX)’s Major holders
RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at JANX for having 9.17 million shares of worth $383.95 million. And as of 2024-06-30, it was holding 16.8326 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 7.78 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.8566 of outstanding shares, having a total worth of $325.8 million.
On the other hand, Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.36 shares of worth $49.11 million or 2.60% of the total outstanding shares. The later fund manager was in possession of 1.0 shares on Sep 30, 2024 , making its stake of worth around $36.07 million in the company or a holder of 1.91% of company’s stock.
